South Dakota State University Stage Production of '1776' [PDF]
, 1975 Scene from the South Dakota State University stage production of "1776.
Stone, Peter, 1930-2003. 1776
core +26 more sources
Therapy optimization of aggressive non-Hodgkin's lymphoma: Preclinical evaluation of GA101 [PDF]
, 2012 Antikörperabhängige zellvermittelte Zytotoxizität (ADCC) ist einer der Hauptwirk-mechanismen monoklonaler anti-CD20-Antikörper bei der Elimination maligner B-Zell-Lymphome. Trotz moderner Immunchemotherapien gibt es Therapieversager.
Schroer, Hinrich
core +1 more source
, 2021 In response to "The 1619 Project", President Donald Trump established a commission to “'enable a rising generation to understand the history and principles of the founding of the United States in 1776 and to strive to form a more perfect Union.'” This ...
The President’s Advisory 1776 Commission
core +2 more sources
Comparaison des mécanismes de cytotoxicité des anticorps monoclonaux anti-CD20 Rituximab et GA101 dans les cellules fraiches de la Leucémie Lymphoïde Chronique [PDF]
, 2010 CD20 is a validated target for the immunotherapy of B lymphoid neoplasms, including ChronicLymphocytic Leukemia (CLL). We compared the activities of rituximab and GA101 (novel anti-CD20 antibody)on fresh human CLL cells in vitro.
Reslan, Lina
core +6 more sources
CD40 stimulation sensitizes CLL cells to lysosomal cell death induction by type II anti-CD20 mAb GA101 [PDF]
, 2011 Sensitivity of chronic lymphocytic leukemia (CLL) cells to anti-CD20 mAbs is low and, therefore, the efficacy of monotherapy with current anti-CD20 mAbs is limited. At present, it is not known whether sensitivity of CLL cells to CD20 mAbs is modulated by
Jak, Margot +19 more
core +1 more source
Mechanism of Action of Type II, Glycoengineered, Anti-CD20 Monoclonal Antibody GA101 in B-Chronic Lymphocytic Leukemia Whole Blood Assays in Comparison with Rituximab and Alemtuzumab [PDF]
, 2011 We analyzed in B-chronic lymphocytic leukemia (B-CLL) whole blood assays the activity of therapeutic mAbs alemtuzumab, rituximab, and type II glycoengineered anti-CD20 mAb GA101.
Martino Introna +6 more
core +1 more source
Role for ZAP-70 Signaling in the Differential Effector Functions of Rituximab and Obinutuzumab (GA101) in Chronic Lymphocytic Leukemia B Cells [PDF]
, 2017 Rituximab (RTX) has been the hallmark anti-CD20 mAb for the treatment of B cell neoplasms, including B cell chronic lymphocytic leukemia (B-CLL). Recently, a novel humanized anti-CD20 mAb obinutuzumab (GA101) has been implemented as first-line CLL ...
William F. C. Rigby +4 more
core +1 more source
Research on Topographic Map Updating
Kartografija i Geoinformacije, 2013 The investigation of interpretability of panchromatic satellite image IRS-1C integrated with multispectral Landsat TM image with the purpose of updating the topographic map sheet at the scale of 1:25 000 has been described.
Ivana Javorović +2 more
doaj
Supplementary Figure 2 from Preclinical Activity of the Type II CD20 Antibody GA101 (Obinutuzumab) Compared with Rituximab and Ofatumumab In Vitro and in Xenograft Models [PDF]
, 2013 PDF file - 307K, Whole-blood B-cell depletion mediated by GA101 (black squares), rituximab (open diamonds), and ofatumumab (open triangles) in lepirudin-treated (A, B) and heat-inactivated (HI) (C) whole-blood samples.
Michael Weidner (15065545) +21 more
core +1 more source